Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
USD9.01
-0.02 (-0.22%)
US NASDAQ Healthcare Biotechnology
Address
500 River Ridge Drive 2062
Norwood, MA, US
Norwood, MA, US
CEO
Yuval Cohen
Website
corbuspharma.com
IPO
2014-10-27
CIK 1595097 ISIN US21833P3010
Also trades on
London Stock Exchange · 0SZI.L (USD)
NASDAQ Capital Market · CRBP (USD)
Description
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.01
-0.02 (-0.22%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
477.5K
Beta
2.59
Float Shares
11.05M
Free Float %
88.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.30% | +11.67% | +19.35% | +60.71% | +9.76% | +49.26% | +67.36% | +15.71% | -70.86% | -82.47% | -86.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (15 ratings, all time)
Buy
Price Targets & DCF
Current price
9.01
Low
33.00
+266.3%
Consensus
33.00
+266.3%
Median
33.00
+266.3%
High
33.00
+266.3%
DCF (Unlevered)
1.97
-78.1%
DCF (Levered)
2.02
-77.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 9 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
43.33
+380.9%
|
| All Time | 13 |
60.92
+576.1%
|
Quality scores
Altman Z-Score
-1.23
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-60.3% Q1'26: +11.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -95.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+22.0% Q1'26: +53.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 7 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
648.4K
est: 876.7K (-26.0%)
|
1.91M
est: 2.26M (-15.4%)
|
2.44M
est: 2.59M (-5.9%)
|
4.82M
est: 3.96M (+21.8%)
|
36.14M
est: 37.27M (-3.0%)
|
3.94M
est: 4.77M (-17.5%)
|
881.7K
est: 1.12M (-21.2%)
|
—
est: 9.98M (-100.0%)
|
—
est: 1.67M (-100.0%)
|
1.67M
1.67M – 1.67M
+0.0% YoY
|
3.60M
3.60M – 3.60M
+116.0% YoY
|
4.52M
4.52M – 4.52M
+25.6% YoY
|
99.02M
99.02M – 99.02M
+2,090.6% YoY
|
291.85M
291.85M – 291.85M
+194.7% YoY
|
| EBITDA |
-8.81M
est: 175.3K (-5,124.6%)
|
-19.90M
est: 451.9K (-4,503.4%)
|
-32.31M
est: 518.8K (-6,327.2%)
|
-56.25M
est: 791.9K (-7,204.0%)
|
-76.37M
est: 7.45M (-1,124.6%)
|
-121.12M
est: 954.7K (-12,786.0%)
|
-54.35M
est: 223.9K (-24,377.8%)
|
-37.74M
est: 5.99M (-730.4%)
|
-78.30M
est: 1.00M (-7,930.4%)
|
1.00M
1.00M – 1.00M
+0.0% YoY
|
2.16M
2.16M – 2.16M
+116.0% YoY
|
2.71M
2.71M – 2.71M
+25.6% YoY
|
59.41M
59.41M – 59.41M
+2,090.6% YoY
|
175.11M
175.11M – 175.11M
+194.7% YoY
|
| EBIT |
-8.85M
est: 175.3K (-5,149.6%)
|
-19.99M
est: 451.9K (-4,522.8%)
|
-32.56M
est: 518.8K (-6,376.5%)
|
-56.75M
est: 791.9K (-7,266.3%)
|
-77.10M
est: 7.45M (-1,134.5%)
|
-122.81M
est: 954.7K (-12,963.5%)
|
-55.99M
est: 223.9K (-25,110.1%)
|
-38.34M
est: 5.99M (-740.4%)
|
-78.54M
est: 1.00M (-7,953.7%)
|
1.00M
1.00M – 1.00M
+0.0% YoY
|
2.16M
2.16M – 2.16M
+116.0% YoY
|
2.71M
2.71M – 2.71M
+25.6% YoY
|
59.41M
59.41M – 59.41M
+2,090.6% YoY
|
175.11M
175.11M – 175.11M
+194.7% YoY
|
| Net Income |
-8.85M
est: -89.50M (+90.1%)
|
-20.00M
est: -146.26M (+86.3%)
|
-32.42M
est: -195.82M (+83.4%)
|
-55.67M
est: -308.89M (+82.0%)
|
-71.45M
est: -352.99M (+79.8%)
|
-111.27M
est: -525.88M (+78.8%)
|
-45.55M
est: -135.07M (+66.3%)
|
-40.21M
est: -57.95M (+30.6%)
|
-78.54M
est: -78.54M (+0.0%)
|
-56.47M
-73.33M – -39.60M
+28.1% YoY
|
-73.11M
-92.36M – -53.87M
-29.5% YoY
|
-67.98M
-99.25M – -36.71M
+7.0% YoY
|
-57.84M
-57.84M – -57.84M
+14.9% YoY
|
8.30M
8.30M – 8.30M
+114.4% YoY
|
| SGA |
3.61M
est: 5.86M (-38.3%)
|
6.46M
est: 15.09M (-57.2%)
|
8.96M
est: 17.33M (-48.3%)
|
12.96M
est: 26.45M (-51.0%)
|
23.64M
est: 248.94M (-90.5%)
|
28.48M
est: 31.89M (-10.7%)
|
20.43M
est: 7.48M (+173.2%)
|
16.50M
est: 54.21M (-69.6%)
|
15.22M
est: 9.06M (+68.0%)
|
9.06M
9.06M – 9.06M
+0.0% YoY
|
19.56M
19.56M – 19.56M
+116.0% YoY
|
24.56M
24.56M – 24.56M
+25.6% YoY
|
537.97M
537.97M – 537.97M
+2,090.6% YoY
|
1.59B
1.59B – 1.59B
+194.7% YoY
|
| EPS |
-8.47
est: -8.20 (-3.3%)
|
-14.58
est: -13.40 (-8.8%)
|
-19.38
est: -17.94 (-8.0%)
|
-29.30
est: -28.30 (-3.5%)
|
-32.47
est: -32.34 (-0.4%)
|
-42.74
est: -48.18 (+11.3%)
|
-11.11
est: -12.38 (+10.2%)
|
-3.68
est: -4.36 (+15.6%)
|
-5.90
est: -6.67 (+11.6%)
|
-4.59
-5.51 – -2.97
+31.3% YoY
|
-5.08
-6.94 – -4.04
-10.7% YoY
|
-5.49
-7.45 – -2.76
-8.1% YoY
|
-4.34
-4.34 – -4.34
+20.9% YoY
|
0.62
0.62 – 0.62
+114.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-64.49M
OE per share TTM
-5.17
Owner's Yield
-43.87%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
98.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Anup Arora | 10.52M | 7.80% | — | 10.52M | — | 10.52M | HC, IN | Delaware | 2024-02-14 | ↗ |
| 2 | K2 HealthVentures Equity Trust LLC | 10.52M | 7.80% | — | 10.52M | — | 10.52M | OO | Delaware | 2024-02-14 | ↗ |
| 3 | Parag Shah | 10.52M | 7.80% | — | 10.52M | — | 10.52M | HC, IN | Delaware | 2024-02-14 | ↗ |
| 4 | ETF Managers Group LLC | 6.19M | 4.95% | 6.19M | — | 6.19M | — | IA | Delaware | 2022-08-24 | ↗ |
| 5 | Bihua Chen | 1.48M | 14.27% | — | 1.48M | — | 1.48M | IN | Delaware | 2024-02-05 | ↗ |
| 6 | Cormorant Asset Management, LP | 1.48M | 14.27% | — | 1.48M | — | 1.48M | PN | Delaware | 2024-02-05 | ↗ |
| 7 | Cormorant Global Healthcare GP, LLC | 1.48M | 14.27% | — | 1.48M | — | 1.48M | OO | Delaware | 2024-02-05 | ↗ |
| 8 | Cormorant Global Healthcare Master Fund, LP | 1.48M | 14.27% | — | 1.48M | — | 1.48M | PN | Delaware | 2024-02-05 | ↗ |
| 9 | NEW DIMENSIONS TRADING LTD. | 1.37M | 5.36% | — | — | 1.37M | — | OO | CAYMAN ISLANDS | 2022-11-21 | ↗ |
| 10 | STATE STREET CORPORATION | 1.33M | 1.59% | — | 1.08M | — | 1.33M | HC | BOSTON, MASSACHUSETTS | 2021-01-11 | ↗ |
| 11 | Octagon Capital Advisors LP | 1.12M | 9.30% | — | 1.12M | — | 1.12M | IA, PN | Delaware | 2024-10-11 | ↗ |
| 12 | Octagon Investments Master Fund LP | 1.12M | 9.30% | — | 1.12M | — | 1.12M | PN, OO | Cayman Islands | 2024-10-11 | ↗ |
| 13 | Ting Jia | 1.12M | 9.30% | — | 1.12M | — | 1.12M | HC, IN | China | 2024-10-11 | ↗ |
| 14 | (1) BlackRock, Inc. | 802.7K | 6.70% | — | — | 802.7K | — | HC | Delaware | 2024-10-22 | ↗ |
| 15 | Adage Capital Management, L.P. | 796.4K | 7.70% | — | 796.4K | — | — | IA, PN | Delaware | 2024-02-12 | ↗ |
| 16 | Adage Capital Partners GP, L.L.C. | 796.4K | 7.70% | — | 796.4K | — | — | OO | Delaware | 2024-02-12 | ↗ |
| 17 | Adage Capital Partners, L.P. | 796.4K | 7.70% | — | 796.4K | — | — | PN | Delaware | 2024-02-12 | ↗ |
| 18 | Phillip Gross | 796.4K | 7.70% | — | 796.4K | — | — | IN | Delaware | 2024-02-12 | ↗ |
| 19 | Robert Atchinson | 796.4K | 7.70% | — | 796.4K | — | — | IN | Delaware | 2024-02-12 | ↗ |
| 20 | OrbiMed Capital LLC | 589.2K | 4.90% | 589.2K | — | 589.2K | — | IA | Delaware | 2024-11-14 | ↗ |
| 21 | Israel A. Englander | 544.3K | 5.30% | — | 544.3K | — | 544.3K | IN | Delaware | 2024-02-28 | ↗ |
| 22 | Millennium Group Management LLC | 544.3K | 5.30% | — | 544.3K | — | 544.3K | OO | Delaware | 2024-02-28 | ↗ |
| 23 | Millennium Management LLC | 544.3K | 5.30% | — | 544.3K | — | 544.3K | OO | Delaware | 2024-02-28 | ↗ |
| 24 | Sphera Funds Management Ltd. | 525.2K | 2.13% | — | 525.2K | — | 525.2K | CO | Israel | 2021-02-16 | ↗ |
| 25 | Sphera Global Healthcare GP Ltd. | 525.2K | 2.13% | — | 525.2K | — | 525.2K | CO | Israel | 2021-02-16 | ↗ |
| 26 | Sphera Global Healthcare Management LP | 525.2K | 2.13% | — | 525.2K | — | 525.2K | CO | Israel | 2021-02-16 | ↗ |
| 27 | s | 430.2K | 4.10% | — | 430.2K | — | 430.2K | PN | Delaware | 2024-02-12 | ↗ |
| 28 | Integrated Core Strategies (US) LLC | 412.3K | 4.00% | — | 412.3K | — | 412.3K | OO | Delaware | 2024-02-09 | ↗ |
| 29 | Point72 Asset Management, L.P. | 388.7K | 8.80% | — | 388.7K | — | — | PN | Delaware | 2024-01-29 | ↗ |
| 30 | Point72 Capital Advisors, Inc. | 388.7K | 8.80% | — | 388.7K | — | — | CO | Delaware | 2024-01-29 | ↗ |
| 31 | Steven A. Cohen | 388.7K | 8.80% | — | 388.7K | — | — | IN | Delaware | 2024-01-29 | ↗ |
| 32 | OrbiMed Advisors LLC | 323.4K | 2.70% | — | 323.4K | — | — | IA | Delaware | 2024-11-14 | ↗ |
| 33 | 2. | 10.00 | 6.00% | — | — | — | — | OO | Delaware | 2023-01-19 | ↗ |
| 34 | Moshe Arkin | 10.00 | 0.00% | — | — | — | — | IN | Israel | 2021-02-16 | ↗ |
| 35 | Paradigm BioCapital Advisors LP | — | 0.00% | — | — | — | — | PN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 40 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.04% | 535.8K | 0.60% |
| 2 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.50M | 0.24% |
| 3 | Fidelity Enhanced Small Cap ETF FESM | 0.01% | 520.2K | 0.28% |
| 4 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 220.7K | 0.25% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.01% | 74.5K | 0.08% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 16.1K | 0.25% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.7K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 4.02M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 26.2K | 0.36% |
| 10 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 134.3K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.33
Neutral
Ratio by volume
3.00
Bullish
Buys
8
Sells
6
Shares acquired
539.2K
Shares disposed
31.2K
Cash buys
—
Cash sales
6.00
Net activity
+508,033
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Smethurst Dominic | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 6,097 | 8.30 | 50.6K | 89,790 | D | ↗ |
| 2026-02-17 | Hodgson Ian | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 847 | 7.38 | 6.3K | 51,080 | D | ↗ |
| 2026-02-13 | Moran Sean F. | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 4,701 | 7.78 | 36.6K | 96,694 | D | ↗ |
| 2026-02-13 | Cohen Yuval | Director / Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 13,871 | 7.78 | 108.0K | 174,316 | D | ↗ |
| 2026-02-03 | Smethurst Dominic | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 3,285 | 8.09 | 26.6K | 95,887 | D | ↗ |
| 2026-02-03 | Hodgson Ian | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 2,415 | 8.09 | 19.5K | 51,927 | D | ↗ |
| 2026-01-14 | Smethurst Dominic | Officer | A-Award | A | Stock options (right to buy) | 85,095 | 8.26 | 702.9K | 85,095 | D | ↗ |
| 2026-01-14 | Moran Sean F. | Officer | A-Award | A | Stock options (right to buy) | 84,247 | 8.26 | 695.9K | 84,247 | D | ↗ |
| 2026-01-14 | Hodgson Ian | Officer | A-Award | A | Common Stock, par value $0.0001 per share | 28,365 | 0.00 | — | 54,342 | D | ↗ |
| 2026-01-14 | Cohen Yuval | Director / Officer | A-Award | A | Common Stock, par value $0.0001 per share | 50,000 | 0.00 | — | 188,187 | D | ↗ |
| 2025-12-11 | Cormorant Asset Management, LP | 10% Owner | S-Sale | D | Common Stock | 30,029 | 11.46 | 344.0K | 2,344,971 | I | ↗ |
| 2025-10-27 | Cohen Yuval | Director / Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 8,973 | 17.14 | 153.8K | 138,187 | D | ↗ |
| 2025-10-24 | Moran Sean F. | Officer | M-Exempt | A | Common Stock, par value $0.0001 per share | 12,981 | 4.26 | 55.3K | 86,294 | D | ↗ |
| 2025-10-24 | Cohen Yuval | Director / Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 18,660 | 17.01 | 317.4K | 138,187 | D | ↗ |
| 2025-10-20 | Altmeyer Anne | Director | M-Exempt | A | Common Stock, par value $0.0001 per share | 1,060 | 4.80 | 5.1K | 7,251 | D | ↗ |
| 2025-05-30 | Kung Winston | Director | A-Award | A | Common Stock, par value $0.0001 per share | 4,800 | 0.00 | — | 10,366 | D | ↗ |
| 2025-05-30 | Jenkins John Kenneth | Director | S-Sale | D | Common Stock, par value $0.0001 per share | 2,783 | 7.35 | 20.5K | 33 | D | ↗ |
| 2025-05-30 | Jacques Rachelle Suzanne | Director | A-Award | A | Common Stock, par value $0.0001 per share | 4,800 | 0.00 | — | 7,583 | D | ↗ |
| 2025-05-30 | HOLMER ALAN F | Director | A-Award | A | Common Stock, par value $0.0001 per share | 4,800 | 0.00 | — | 10,629 | D | ↗ |
| 2025-05-30 | Ben Yong | Director | A-Award | A | Common Stock, par value $0.0001 per share | 4,800 | 0.00 | — | 7,583 | D | ↗ |
| 2025-05-30 | Altmeyer Anne | Director | A-Award | A | Stock options (right to buy) | 16,000 | 7.42 | 118.7K | 16,000 | D | ↗ |
| 2025-03-13 | Hodgson Ian | Officer | — | — | Stock options (right to buy) | 60,000 | 9.79 | 587.4K | 0 | D | ↗ |
| 2025-03-06 | Smethurst Dominic | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 6,393 | 6.78 | 43.3K | 70,807 | D | ↗ |
| 2025-02-14 | Moran Sean F. | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 2,792 | 8.76 | 24.4K | 73,313 | D | ↗ |
| 2025-02-14 | Cohen Yuval | Director / Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 7,134 | 8.76 | 62.5K | 138,187 | D | ↗ |
| 2025-01-31 | Smethurst Dominic | Officer | A-Award | A | Stock options (right to buy) | 91,200 | 9.79 | 892.8K | 91,200 | D | ↗ |
| 2025-01-31 | Moran Sean F. | Officer | A-Award | A | Stock options (right to buy) | 92,500 | 9.79 | 905.6K | 92,500 | D | ↗ |
| 2025-01-31 | Cohen Yuval | Director / Officer | A-Award | A | Stock options (right to buy) | 228,800 | 9.79 | 2.24M | 228,800 | D | ↗ |
| 2024-09-20 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 66,088 | 19.61 | 1.30M | 2,162,116 | I | ↗ |
| 2024-08-16 | Kung Winston | Director | A-Award | A | Stock options (right to buy) | 5,566 | 53.52 | 297.9K | 5,566 | — | ↗ |
| 2024-06-18 | Moran Sean F. | Officer | M-Exempt | D | Options to purchase common stock | 1,958 | 30.00 | 58.7K | 0 | — | ↗ |
| 2024-06-18 | Cohen Yuval | Director / Officer | M-Exempt | D | Options to purchase common stock | 11,667 | 30.00 | 350.0K | 0 | — | ↗ |
| 2024-06-17 | Moran Sean F. | Officer | M-Exempt | D | Options to purchase common stock | 6,730 | 14.10 | 94.9K | 11,217 | — | ↗ |
| 2024-06-17 | Cohen Yuval | Director / Officer | M-Exempt | D | Options to purchase common stock | 1,770 | 4.26 | 7.5K | 52,061 | — | ↗ |
| 2024-06-14 | Moran Sean F. | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 7,788 | 49.87 | 388.4K | 48,605 | — | ↗ |
| 2024-06-14 | HOLMER ALAN F | Director | M-Exempt | D | Options to purchase common stock | 1,667 | 30.00 | 50.0K | 0 | — | ↗ |
| 2024-06-14 | Cohen Yuval | Director / Officer | M-Exempt | D | Options to purchase common stock | 16,830 | 14.10 | 237.3K | 32,827 | — | ↗ |
| 2024-05-30 | Salzmann Peter | Director | A-Award | A | Common Stock, par value $0.0001 per share | 2,783 | 0.00 | — | 2,783 | — | ↗ |
| 2024-05-30 | Jenkins John Kenneth | Director | A-Award | A | Common Stock, par value $0.0001 per share | 2,783 | 0.00 | — | 2,816 | — | ↗ |
| 2024-05-30 | Jacques Rachelle Suzanne | Director | A-Award | A | Common Stock, par value $0.0001 per share | 2,783 | 0.00 | — | 2,783 | — | ↗ |
| 2024-05-30 | HOLMER ALAN F | Director | A-Award | A | Common Stock, par value $0.0001 per share | 2,783 | 0.00 | — | 4,162 | — | ↗ |
| 2024-05-30 | CATLIN AVERY W | Director | A-Award | A | Common Stock, par value $0.0001 per share | 2,783 | 0.00 | — | 4,350 | — | ↗ |
| 2024-05-30 | Ben Yong | Director | A-Award | A | Common Stock, par value $0.0001 per share | 2,783 | 0.00 | — | 2,783 | — | ↗ |
| 2024-05-30 | Altmeyer Anne | Director | A-Award | A | Common Stock, par value $0.0001 per share | 2,783 | 0.00 | — | 2,783 | — | ↗ |
| 2024-05-16 | Salzmann Peter | Director | A-Award | A | Stock Option (right to buy) | 2,783 | 45.92 | 127.8K | 2,783 | — | ↗ |
| 2024-05-16 | Jenkins John Kenneth | Director | A-Award | A | Stock Option (right to buy) | 2,783 | 45.92 | 127.8K | 2,783 | — | ↗ |
| 2024-05-16 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option (right to buy) | 2,783 | 45.92 | 127.8K | 2,783 | — | ↗ |
| 2024-05-16 | HOLMER ALAN F | Director | A-Award | A | Stock Option (right to buy) | 2,783 | 45.92 | 127.8K | 2,783 | — | ↗ |
| 2024-05-16 | CATLIN AVERY W | Director | A-Award | A | Stock Option (right to buy) | 2,783 | 45.92 | 127.8K | 2,783 | — | ↗ |
| 2024-05-16 | Ben Yong | Director | A-Award | A | Stock Option (right to buy) | 2,783 | 45.92 | 127.8K | 2,783 | — | ↗ |
| 2024-05-16 | Altmeyer Anne | Director | A-Award | A | Stock Option (right to buy) | 2,783 | 45.92 | 127.8K | 2,783 | — | ↗ |
| 2024-04-10 | Moran Sean F. | Officer | M-Exempt | A | Common Stock | 1,787 | 30.00 | 53.6K | 48,605 | — | ↗ |
| 2024-03-08 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 29,342 | 41.23 | 1.21M | 1,754,342 | — | ↗ |
| 2024-03-07 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 102,140 | 41.23 | 4.21M | 1,725,000 | — | ↗ |
| 2024-02-27 | Smethurst Dominic | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-12 | Moran Sean F. | Officer | A-Award | A | Common Stock, par value $0.0001 per share | 40,176 | 0.00 | — | 46,818 | — | ↗ |
| 2024-02-12 | Cohen Yuval | Director / Officer | A-Award | A | Common Stock, par value $0.0001 per share | 73,947 | 0.00 | — | 84,400 | — | ↗ |
| 2024-02-02 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 750,000 | 19.00 | 14.25M | 1,475,000 | — | ↗ |
| 2024-01-26 | HOLMER ALAN F | Director | M-Exempt | D | Options to purchase common stock | 629 | 4.97 | 3.1K | 0 | — | ↗ |
| 2024-01-26 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 36,747 | 27.70 | 1.02M | 508,746 | — | ↗ |
| 2024-01-26 | Cohen Yuval | Director / Officer | M-Exempt | D | Options to purchase common stock | 7,179 | 4.97 | 35.7K | 0 | — | ↗ |
| 2023-05-18 | Salzmann Peter | Director | A-Award | A | Stock Option (right to buy) | 5,300 | 9.96 | 52.8K | 5,300 | — | ↗ |
| 2023-05-18 | Jenkins John Kenneth | Director | A-Award | A | Stock Option (right to buy) | 5,300 | 9.96 | 52.8K | 5,300 | — | ↗ |
| 2023-05-18 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option (right to buy) | 5,300 | 9.96 | 52.8K | 5,300 | — | ↗ |
| 2023-05-18 | HOLMER ALAN F | Director | A-Award | A | Stock Option (right to buy) | 5,300 | 9.96 | 52.8K | 5,300 | — | ↗ |
| 2023-05-18 | CATLIN AVERY W | Director | A-Award | A | Stock Option (right to buy) | 5,300 | 9.96 | 52.8K | 5,300 | — | ↗ |
| 2023-05-18 | Ben Yong | Director | A-Award | A | Stock Option (right to buy) | 5,300 | 9.96 | 52.8K | 5,300 | — | ↗ |
| 2023-05-18 | Altmeyer Anne | Director | A-Award | A | Stock Option (right to buy) | 5,300 | 9.96 | 52.8K | 5,300 | — | ↗ |
| 2023-03-06 | Ben Yong | Director | A-Award | A | Stock Option(right to buy) | 5,307 | 2.85 | 15.1K | 5,307 | — | ↗ |
| 2023-02-13 | Moran Sean F. | Officer | A-Award | A | Stock Option (right to buy) | 934,645 | 0.14 | 132.7K | 934,645 | — | ↗ |
| 2023-02-13 | Millian Craig Stuart | Officer | A-Award | A | Stock Option (right to buy) | 934,645 | 0.14 | 132.7K | 934,645 | — | ↗ |
| 2023-02-13 | Cohen Yuval | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,989,546 | 0.14 | 282.5K | 1,949,546 | — | ↗ |
| 2023-02-13 | Brake Rachael Louise | Officer | A-Award | A | Stock Option (right to buy) | 1,400,000 | 0.14 | 198.8K | 1,400,000 | — | ↗ |
| 2022-08-10 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 20,000 | 0.26 | 5.2K | 199,272 | — | ↗ |
| 2022-08-10 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 5,000 | 0.25 | 1.3K | 27,000 | — | ↗ |
| 2022-08-10 | Cohen Yuval | Officer | P-Purchase | A | Common Stock | 3,800 | 0.26 | 1.0K | 98,230 | — | ↗ |
| 2022-05-18 | Salzmann Peter | Director | A-Award | A | Stock Option(right to buy) | 79,600 | 0.00 | — | 79,600 | — | ↗ |
| 2022-05-18 | Jenkins John Kenneth | Director | A-Award | A | Stock Option(right to buy) | 79,600 | 0.33 | 26.3K | 79,600 | — | ↗ |
| 2022-05-18 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option(right to buy) | 79,600 | 0.00 | — | 79,600 | — | ↗ |
| 2022-05-18 | HOLMER ALAN F | Director | A-Award | A | Stock Option(right to buy) | 79,600 | 0.00 | — | 79,600 | — | ↗ |
| 2022-05-18 | CATLIN AVERY W | Director | A-Award | A | Stock Option(right to buy) | 79,600 | 0.33 | 26.3K | 79,600 | — | ↗ |
| 2022-05-16 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 12,000 | 0.30 | 3.6K | 179,272 | — | ↗ |
| 2022-05-16 | Cohen Yuval | Officer | P-Purchase | A | Common Stock | 10,500 | 0.25 | 2.6K | 94,430 | — | ↗ |
| 2022-03-10 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 15,000 | 0.37 | 5.6K | 167,272 | — | ↗ |
| 2022-03-10 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 10,000 | 0.37 | 3.7K | 22,000 | — | ↗ |
| 2022-03-09 | Cohen Yuval | Officer | P-Purchase | A | Common Stock | 8,600 | 0.37 | 3.2K | 83,930 | — | ↗ |
| 2022-02-01 | Moran Sean F. | Officer | A-Award | A | Stock Option (right to buy) | 538,400 | 0.47 | 253.0K | 538,400 | — | ↗ |
| 2022-02-01 | Millian Craig Stuart | Officer | A-Award | A | Stock Option (right to buy) | 402,900 | 0.47 | 189.4K | 402,900 | — | ↗ |
| 2022-02-01 | Cohen Yuval | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,489,700 | 0.47 | 700.2K | 1,489,700 | — | ↗ |
| 2022-02-01 | Brake Rachael Louise | Officer | A-Award | A | Stock Option (right to buy) | 570,800 | 0.47 | 268.3K | 570,800 | — | ↗ |
| 2021-12-06 | Brake Rachael Louise | Officer | A-Award | A | Stock Option(right to buy) | 500,000 | 0.75 | 373.7K | 500,000 | — | ↗ |
| 2021-06-17 | Salzmann Peter | Director | A-Award | A | Stock Option (right to buy) | 58,200 | 2.07 | 120.5K | 58,200 | — | ↗ |
| 2021-06-17 | Jenkins John Kenneth | Director | A-Award | A | Stock Option (right to buy) | 58,200 | 2.07 | 120.5K | 58,200 | — | ↗ |
| 2021-06-17 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option (right to buy) | 58,200 | 2.07 | 120.5K | 58,200 | — | ↗ |
| 2021-06-17 | HOLMER ALAN F | Director | A-Award | A | Stock Option (right to buy) | 58,200 | 2.07 | 120.5K | 58,200 | — | ↗ |
| 2021-06-17 | CATLIN AVERY W | Director | A-Award | A | Stock Option (right to buy) | 58,200 | 2.07 | 120.5K | 58,200 | — | ↗ |
| 2021-02-02 | White Barbara | Officer | A-Award | A | Stock Option (right to buy) | 307,300 | 2.58 | 792.8K | 307,300 | — | ↗ |
| 2021-02-02 | Moran Sean F. | Officer | A-Award | A | Stock Option (right to buy) | 307,300 | 2.58 | 792.8K | 307,300 | — | ↗ |
| 2021-02-02 | Millian Craig Stuart | Officer | A-Award | A | Stock Option (right to buy) | 307,300 | 2.58 | 792.8K | 307,300 | — | ↗ |
| 2021-02-02 | Cohen Yuval | Director / Officer | A-Award | A | Stock Option (right to buy) | 956,500 | 2.58 | 2.47M | 956,500 | — | ↗ |
| 2020-12-21 | Moran Sean F. | Officer | M-Exempt | A | Common Stock | 87,500 | 1.40 | 122.5K | 437,110 | — | ↗ |
| 2020-12-18 | Moran Sean F. | Officer | S-Sale | D | Common Stock | 53,610 | 1.40 | 75.1K | 349,610 | — | ↗ |
| 2020-12-16 | Moran Sean F. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 36,923 | 0.17 | 6.1K | 36,923 | — | ↗ |
| 2020-11-11 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 4,240 | 1.21 | 5.1K | 75,330 | — | ↗ |
| 2020-07-06 | Golumbeski George | Director | A-Award | A | Stock Option(right to buy) | 81,000 | 7.91 | 640.7K | 81,000 | — | ↗ |
| 2020-05-20 | Salzmann Peter | Director | A-Award | A | Stock Option(right to buy) | 40,500 | 7.30 | 295.7K | 40,500 | — | ↗ |
| 2020-05-20 | Jenkins John Kenneth | Director | A-Award | A | Stock Option(right to buy) | 40,500 | 7.30 | 295.7K | 40,500 | — | ↗ |
| 2020-05-20 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option(right to buy) | 40,500 | 7.30 | 295.7K | 40,500 | — | ↗ |
| 2020-05-20 | Hochman David P | Director | A-Award | A | Stock Option(right to buy) | 40,500 | 7.30 | 295.7K | 40,500 | — | ↗ |
| 2020-05-20 | HOLMER ALAN F | Director | A-Award | A | Stock Option(right to buy) | 40,500 | 7.30 | 295.7K | 40,500 | — | ↗ |
| 2020-05-20 | CATLIN AVERY W | Director | A-Award | A | Stock Option(right to buy) | 40,500 | 7.30 | 295.7K | 40,500 | — | ↗ |
| 2020-03-17 | White Barbara | Officer | P-Purchase | A | Common Stock | 15,606 | 3.63 | 56.6K | 206,217 | — | ↗ |
| 2020-03-17 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 2,000 | 4.25 | 8.5K | 12,000 | — | ↗ |
| 2020-03-17 | Discordia Robert Paul | Officer | P-Purchase | A | Common Stock | 2,840 | 3.54 | 10.1K | 35,490 | — | ↗ |
| 2020-03-17 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 4,300 | 3.49 | 15.0K | 71,090 | — | ↗ |
| 2020-03-06 | White Barbara | Officer | A-Award | A | Stock Option(right to buy) | 226,000 | 4.53 | 1.02M | 226,000 | — | ↗ |
| 2020-03-06 | Salzmann Peter | Director | A-Award | A | Stock Option(right to buy) | 66,600 | 4.53 | 301.7K | 66,600 | — | ↗ |
| 2020-03-06 | Moran Sean F. | Officer | A-Award | A | Stock Option(right to buy) | 226,000 | 4.53 | 1.02M | 226,000 | — | ↗ |
| 2020-03-06 | Millian Craig Stuart | Officer | A-Award | A | Stock Option(right to buy) | 226,000 | 4.53 | 1.02M | 226,000 | — | ↗ |
| 2020-03-06 | Discordia Robert Paul | Officer | A-Award | A | Stock Option(right to buy) | 226,000 | 4.53 | 1.02M | 226,000 | — | ↗ |
| 2020-03-06 | Cohen Yuval | Director / Officer | A-Award | A | Stock Option(right to buy) | 639,000 | 4.53 | 2.89M | 639,000 | — | ↗ |
| 2019-11-12 | White Barbara | Officer | P-Purchase | A | Common Stock | 3,424 | 4.38 | 15.0K | 190,611 | — | ↗ |
| 2019-11-12 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 1,430 | 4.26 | 6.1K | 66,790 | — | ↗ |
| 2019-11-11 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 1,000 | 4.38 | 4.4K | 10,000 | — | ↗ |
| 2019-11-11 | Discordia Robert Paul | Officer | P-Purchase | A | Common Stock | 2,500 | 4.62 | 11.6K | 32,650 | — | ↗ |
| 2019-08-15 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 1,500 | 5.48 | 8.2K | 9,000 | — | ↗ |
| 2019-08-12 | White Barbara | Officer | P-Purchase | A | Common Stock | 1,639 | 6.10 | 10.0K | 187,187 | — | ↗ |
| 2019-08-12 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 1,500 | 6.00 | 9.0K | 7,500 | — | ↗ |
| 2019-08-12 | Discordia Robert Paul | Officer | P-Purchase | A | Common Stock | 15,000 | 5.86 | 87.9K | 30,150 | — | ↗ |
| 2019-08-12 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 1,175 | 6.06 | 7.1K | 65,360 | — | ↗ |
| 2019-08-06 | Discordia Robert Paul | Officer | A-Award | A | Stock Option(right to buy) | 100,000 | 5.64 | 564.0K | 100,000 | — | ↗ |
| 2019-05-22 | Panayiotopoulos Paris | Director | A-Award | A | Stock Option(right to buy) | 33,300 | 7.31 | 243.4K | 33,300 | — | ↗ |
| 2019-05-22 | Jenkins John Kenneth | Director | A-Award | A | Stock Option(right to buy) | 33,300 | 7.31 | 243.4K | 33,300 | — | ↗ |
| 2019-05-22 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option(right to buy) | 33,300 | 7.31 | 243.4K | 33,300 | — | ↗ |
| 2019-05-22 | Hochman David P | Director | A-Award | A | Stock Option(right to buy) | 33,300 | 7.31 | 243.4K | 33,300 | — | ↗ |
| 2019-05-22 | HOLMER ALAN F | Director | A-Award | A | Stock Option(right to buy) | 33,300 | 7.31 | 243.4K | 33,300 | — | ↗ |
| 2019-05-22 | CATLIN AVERY W | Director | A-Award | A | Stock Option(right to buy) | 33,300 | 7.31 | 243.4K | 33,300 | — | ↗ |
| 2019-05-17 | White Barbara | Officer | P-Purchase | A | Common Stock | 1,389 | 7.20 | 10.0K | 185,548 | — | ↗ |
| 2019-05-14 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 100 | 7.12 | 712.00 | 349,610 | — | ↗ |
| 2019-05-14 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 1,000 | 7.23 | 7.2K | 6,000 | — | ↗ |
| 2019-05-13 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 995 | 6.99 | 7.0K | 64,185 | — | ↗ |
| 2019-04-05 | Jacques Rachelle Suzanne | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-15 | Jenkins John Kenneth | Director | P-Purchase | A | Common Stock | 1,000 | 6.98 | 7.0K | 1,000 | — | ↗ |
| 2019-03-15 | Hochman David P | Director | P-Purchase | A | Common Stock | 2,000 | 6.98 | 14.0K | 7,000 | — | ↗ |
| 2019-03-14 | White Barbara | Officer | P-Purchase | A | Common Stock | 4,638 | 6.47 | 30.0K | 184,159 | — | ↗ |
| 2019-03-14 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 1,500 | 6.67 | 10.0K | 349,510 | — | ↗ |
| 2019-03-14 | Millian Craig Stuart | Officer | P-Purchase | A | Common Stock | 5,000 | 6.85 | 34.3K | 5,000 | — | ↗ |
| 2019-03-14 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 1,530 | 6.49 | 9.9K | 63,190 | — | ↗ |
| 2019-02-28 | Millian Craig Stuart | Officer | A-Award | A | Stock Option(right to buy) | 180,000 | 6.94 | 1.25M | 180,000 | — | ↗ |
| 2019-01-18 | White Barbara | Officer | A-Award | A | Stock Option(right to buy) | 195,000 | 7.53 | 1.47M | 195,000 | — | ↗ |
| 2019-01-18 | Tepper Mark | Officer | A-Award | A | Stock Option(right to buy) | 195,000 | 7.53 | 1.47M | 195,000 | — | ↗ |
| 2019-01-18 | Moran Sean F. | Officer | A-Award | A | Stock Option(right to buy) | 195,000 | 7.53 | 1.47M | 195,000 | — | ↗ |
| 2019-01-18 | Cohen Yuval | Director / Officer | A-Award | A | Stock Option(right to buy) | 565,000 | 7.53 | 4.25M | 565,000 | — | ↗ |
| 2018-11-14 | Tepper Mark | Officer | M-Exempt | A | Common Stock | 10,000 | 1.00 | 10.0K | 2,110,400 | — | ↗ |
| 2018-06-05 | Jenkins John Kenneth | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-05-24 | Panayiotopoulos Paris | Director | A-Award | A | Stock Option(right to buy) | 34,000 | 5.93 | 201.6K | 34,000 | — | ↗ |
| 2018-05-24 | Hochman David P | Director | G-Gift | A | Common Stock | 110,000 | 0.00 | — | 120,000 | — | ↗ |
| 2018-05-24 | HOLMER ALAN F | Director | A-Award | A | Stock Option(right to buy) | 34,000 | 5.93 | 201.6K | 34,000 | — | ↗ |
| 2018-05-24 | CATLIN AVERY W | Director | A-Award | A | Stock Option(right to buy) | 34,000 | 5.93 | 201.6K | 34,000 | — | ↗ |
| 2018-05-15 | White Barbara | Officer | P-Purchase | A | Common Stock | 2,586 | 5.87 | 15.2K | 179,521 | — | ↗ |
| 2018-05-15 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 4,000 | 5.77 | 23.1K | 348,010 | — | ↗ |
| 2018-05-15 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 1,725 | 5.85 | 10.1K | 61,660 | — | ↗ |
| 2018-05-14 | Hochman David P | Director | P-Purchase | A | Common Stock | 5,000 | 5.48 | 27.4K | 5,000 | — | ↗ |
| 2018-03-14 | White Barbara | Officer | P-Purchase | A | Common Stock | 2,885 | 6.89 | 19.9K | 176,935 | — | ↗ |
| 2018-03-14 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 3,100 | 6.60 | 20.5K | 344,010 | — | ↗ |
| 2018-03-14 | Hochman David P | Director | P-Purchase | A | Common Stock | 5,000 | 6.67 | 33.3K | 225,000 | — | ↗ |
| 2018-03-14 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 1,160 | 6.89 | 8.0K | 59,935 | — | ↗ |
| 2018-01-04 | White Barbara | Officer | A-Award | A | Stock Option(right to buy) | 175,000 | 8.35 | 1.46M | 175,000 | — | ↗ |
| 2018-01-04 | Tepper Mark | Officer | A-Award | A | Stock Option(right to buy) | 175,000 | 8.35 | 1.46M | 175,000 | — | ↗ |
| 2018-01-04 | Moran Sean F. | Officer | A-Award | A | Stock Option(right to buy) | 175,000 | 8.35 | 1.46M | 175,000 | — | ↗ |
| 2018-01-04 | Cohen Yuval | Director / Officer | A-Award | A | Stock Option(right to buy) | 437,500 | 8.35 | 3.65M | 437,500 | — | ↗ |
| 2017-11-16 | Panayiotopoulos Paris | Director | P-Purchase | A | Common Stock | 14,285 | 7.03 | 100.4K | 14,285 | — | ↗ |
| 2017-11-15 | Hochman David P | Director | P-Purchase | A | Common Stock | 5,000 | 6.55 | 32.8K | 220,000 | — | ↗ |
| 2017-11-13 | Hochman David P | Director | P-Purchase | A | Common Stock | 5,000 | 6.90 | 34.5K | 215,000 | — | ↗ |
| 2017-11-10 | White Barbara | Officer | P-Purchase | A | Common Stock | 2,836 | 7.00 | 19.9K | 174,050 | — | ↗ |
| 2017-11-10 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 1,500 | 7.04 | 10.6K | 340,910 | — | ↗ |
| 2017-11-10 | Hochman David P | Director | P-Purchase | A | Common Stock | 10,000 | 7.08 | 70.8K | 459,500 | — | ↗ |
| 2017-11-10 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 7.17 | 7.2K | 58,775 | — | ↗ |
| 2017-10-16 | Panayiotopoulos Paris | Director | A-Award | A | Stock Option(right to buy) | 61,000 | 6.90 | 420.9K | 61,000 | — | ↗ |
| 2017-08-11 | White Barbara | Officer | P-Purchase | A | Common Stock | 2,479 | 6.05 | 15.0K | 171,214 | — | ↗ |
| 2017-08-11 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 2,500 | 5.91 | 14.8K | 339,410 | — | ↗ |
| 2017-08-11 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 1,695 | 6.00 | 10.2K | 57,775 | — | ↗ |
| 2017-05-25 | Hochman David P | Director | A-Award | A | Stock Option(right to buy) | 30,500 | 6.75 | 205.9K | 30,500 | — | ↗ |
| 2017-05-25 | HOLMER ALAN F | Director | A-Award | A | Stock Option(right to buy) | 30,500 | 6.75 | 205.9K | 30,500 | — | ↗ |
| 2017-05-25 | GUPTA RENU | Director | A-Award | A | Stock Option(right to buy) | 30,500 | 6.75 | 205.9K | 30,500 | — | ↗ |
| 2017-05-25 | CATLIN AVERY W | Director | A-Award | A | Stock Option(right to buy) | 30,500 | 6.75 | 205.9K | 30,500 | — | ↗ |
| 2017-05-11 | White Barbara | Officer | P-Purchase | A | Common Stock | 2,435 | 6.12 | 14.9K | 168,735 | — | ↗ |
| 2017-05-11 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 3,300 | 6.14 | 20.3K | 336,910 | — | ↗ |
| 2017-05-11 | Hochman David P | Director | P-Purchase | A | Common Stock | 3,400 | 6.18 | 21.0K | 459,500 | — | ↗ |
| 2017-05-11 | HOLMER ALAN F | Director | P-Purchase | A | Common Stock | 500 | 6.23 | 3.1K | 22,500 | — | ↗ |
| 2017-05-11 | Cohen Yuval | Director / Officer | P-Purchase | A | Common Stock | 3,250 | 6.01 | 19.5K | 56,080 | — | ↗ |
| 2017-05-11 | CATLIN AVERY W | Director | P-Purchase | A | Common Stock | 5,000 | 6.15 | 30.7K | 47,000 | — | ↗ |
| 2017-03-17 | White Barbara | Officer | P-Purchase | A | Common Stock | 4,233 | 9.49 | 40.2K | 166,300 | — | ↗ |
| 2017-03-16 | Cohen Yuval | Director / Officer | M-Exempt | D | Options to purchase common stock | 20,000 | 1.00 | 20.0K | 272,728 | — | ↗ |
| 2017-03-13 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 2,000 | 9.60 | 19.2K | 333,610 | — | ↗ |
| 2017-03-01 | White Barbara | Officer | A-Award | A | Stock Option(right to buy) | 115,000 | 9.05 | 1.04M | 115,000 | — | ↗ |
| 2017-03-01 | Tepper Mark | Officer | A-Award | A | Stock Option(right to buy) | 115,000 | 9.05 | 1.04M | 115,000 | — | ↗ |
| 2017-03-01 | Moran Sean F. | Officer | A-Award | A | Stock Option(right to buy) | 115,000 | 9.05 | 1.04M | 115,000 | — | ↗ |
| 2017-03-01 | Cohen Yuval | Director / Officer | A-Award | A | Stock Option(right to buy) | 377,500 | 9.05 | 3.42M | 377,500 | — | ↗ |
| 2016-12-02 | Moran Sean F. | Officer | P-Purchase | A | Common Stock | 1,500 | 7.20 | 10.8K | 331,610 | — | ↗ |
Executive team
Top executives
Shares Outstanding
12.54M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Yuval Cohen Chief Executive Officer | 646.6K | 373.7K | 666.7K | 2.04M | — | 23.9K | 3.75M | 72.16% | ↗ |
| 2 | 2025 | Dominic Smethurst Chief Medical Officer | 519.3K | 168.1K | 266.3K | 812.9K | — | 33.6K | 1.80M | 59.95% | ↗ |
| 3 | 2025 | Sean Moran Chief Financial Officer | 481.1K | 185.4K | 269.2K | 824.5K | — | 29.2K | 1.79M | 61.12% | ↗ |
| 4 | 2024 | Yuval Cohen Chief Executive Officer | 621.9K | 380.9K | 1.70M | 1.52M | — | 23.0K | 4.25M | 75.84% | ↗ |
| 5 | 2024 | Dominic Smethurst Chief Medical Officer | 408.9K | — | 1.30M | 1.17M | — | 14.9K | 2.89M | 85.35% | ↗ |
| 6 | 2024 | Sean Moran Chief Financial Officer | 462.8K | 188.9K | 924.0K | 825.2K | — | 28.5K | 2.43M | 72.00% | ↗ |
| 7 | 2023 | Yuval Cohen Chief Executive Officer | 598.9K | 283.9K | — | 229.8K | — | 25.1K | 1.14M | 20.20% | ↗ |
| 8 | 2023 | Rachael Brake Chief Scientific Officer | 454.0K | 200.0K | — | 161.7K | — | 24.2K | 839.9K | 19.26% | ↗ |
| 9 | 2023 | Sean Moran Chief Financial Officer | 445.0K | 135.4K | — | 108.0K | — | 28.9K | 717.3K | 15.05% | ↗ |
| 10 | 2022 | Yuval Cohen Chief Executive Officer | 598.1K | 277.7K | — | 552.2K | — | 14.9K | 1.44M | 38.27% | ↗ |
| 11 | 2022 | Sean Moran Chief Financial Officer | 427.9K | 132.5K | — | 199.6K | — | 18.6K | 778.6K | 25.63% | ↗ |
| 12 | 2022 | Rachael Brake Chief Scientific Officer | 427.8K | 109.0K | — | 211.6K | — | 15.5K | 763.8K | 27.70% | ↗ |
| 13 | 2021 | Yuval Cohen Chief Executive Officer | 578.7K | 268.3K | — | 4.00M | — | 14.7K | 4.86M | 82.26% | ↗ |
| 14 | 2021 | Sean Moran Chief Financial Officer | 414.1K | 128.0K | — | 1.28M | — | 18.9K | 1.84M | 69.60% | ↗ |
| 15 | 2021 | Rachael Brake Chief Scientific Officer | 15.8K | — | — | — | — | 38.00 | 15.8K | 0.00% | ↗ |
| 16 | 2017 | Yuval Cohen Chief Executive Officer | 463.0K | 267.4K | — | 2.51M | — | — | 3.24M | 77.47% | ↗ |
| 17 | 2017 | Barbara White Chief Medical Officer | 378.0K | 158.8K | — | 765.2K | — | — | 1.30M | 58.77% | ↗ |
| 18 | 2017 | Mark Tepper President and Chief Scientific Officer | 349.0K | 164.9K | — | 765.2K | — | — | 1.28M | 59.82% | ↗ |
| 19 | 2017 | Sean Moran Chief Financial Officer | 335.0K | 140.7K | — | 765.2K | — | — | 1.24M | 61.67% | ↗ |
| 20 | 2016 | Yuval Cohen Chief Executive Officer | 370.0K | 185.0K | — | 1.49M | — | — | 2.05M | 72.91% | ↗ |
| 21 | 2016 | Barbara White Chief Medical Officer | 345.0K | 138.0K | — | 1.19M | — | — | 1.67M | 71.15% | ↗ |
| 22 | 2016 | Mark Tepper President and Chief Scientific Officer | 320.0K | 144.0K | — | 1.19M | — | — | 1.66M | 71.96% | ↗ |
| 23 | 2016 | Sean Moran Chief Financial Officer | 305.0K | 122.0K | — | 1.12M | — | — | 1.55M | 72.46% | ↗ |
| 24 | 2015 | Barbara White Chief Medical Officer | 300.0K | 136.1K | — | — | — | — | 436.1K | 0.00% | ↗ |
| 25 | 2015 | Yuval Cohen Chief Executive Officer | 240.0K | 137.0K | — | — | — | — | 377.0K | 0.00% | ↗ |
| 26 | 2015 | Mark Tepper President and Chief Scientific Officer | 240.0K | 137.0K | — | — | — | — | 377.0K | 0.00% | ↗ |
| 27 | 2014 | Yuval Cohen Chief Executive Officer | 175.0K | 45.0K | — | 681.7K | — | — | 901.7K | 75.60% | ↗ |
| 28 | 2014 | Mark Tepper President and Chief Scientific Officer | 211.1K | — | — | 345.6K | — | — | 556.7K | 62.08% | ↗ |
| 29 | 2014 | Sean Moran Chief Financial Officer | 145.6K | 20.0K | — | 230.0K | — | — | 395.6K | 58.13% | ↗ |
| 30 | 2014 | Barbara White Chief Medical Officer | 102.7K | — | — | 108.8K | — | — | 211.5K | 51.45% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuval Cohen | Chief Executive Officer & Director | 1M | — |
| Dominic Smethurst | Chief Medical Officer | 721.0K | — |
| Sean F. Moran | Chief Financial Officer | 695.7K | male |
| Christina Bertsch | Vice President of Human Resources | — | female |
| G. Scott Goeken | General Counsel & Corporate Secretary | — | male |
| Ian Hodgson | Chief Operating Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRBP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
